期刊
ONCOGENE
卷 37, 期 40, 页码 5451-5465出版社
SPRINGERNATURE
DOI: 10.1038/s41388-018-0326-9
关键词
-
资金
- Alex's Lemonade Stand Foundation
- Hyundai Hope on Wheels
- Cancer Target Discovery and Development Consortium
- National Cancer Institute (NCI) Outstanding Investigator Award [R35CA197745-02]
- [NIH-1S10OD021764]
- [NIH-1S10OD012351]
Despite the identification of MYCN amplification as an adverse prognostic marker in neuroblastoma, MYCN inhibitors have yet to be developed. Here, by integrating evidence from a whole-genome shRNA library screen and the computational inference of master regulator proteins, we identify transcription factor activating protein 4 (TFAP4) as a critical effector of MYCN amplification in neuroblastoma, providing a novel synthetic lethal target. We demonstrate that TFAP4 is a direct target of MYCN in neuroblastoma cells, and that its expression and activity strongly negatively correlate with neuroblastoma patient survival. Silencing TFAP4 selectively inhibits MYCN-amplified neuroblastoma cell growth both in vitro and in vivo, in xenograft mouse models. Mechanistically, silencing TFAP4 induces neuroblastoma differentiation, as evidenced by increased neurite outgrowth and upregulation of neuronal markers. Taken together, our results demonstrate that TFAP4 is a key regulator of MYCN-amplified neuroblastoma and may represent a valuable novel therapeutic target.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据